Mutations in the TP53 tumour suppressor gene are very frequent in cancer, and attempts to
restore the functionality of p53 in tumours as a therapeutic strategy began decades ago …

The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

PURPOSE Approximately 20% of patients with TP53-mutant myelodysplastic syndromes
(MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …

PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) have very poor outcome irrespective of the treatment received, including …

Simple Summary The transcription factor p53 is a crucial tumor suppressor that regulates
diverse cellular responses to protect against cancer development. Deactivating p53 …

Abstract p53 is a key tumor suppressor, and loss of p53 function is frequently a prerequisite
for cancer development. The p53 gene is the most frequently mutated gene in human …

TP53 is the most frequently mutated tumor suppressor gene in human cancer. The majority
of mutations of p53 are missense mutations, leading to the expression of the full length p53 …